NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

In Vitro Activity of Tigecycline Compared with other Antimicrobial Agents against Recent Clinical Isolates of Methicillin-Resistant Staphylococcus aureus.

PICAZO JJ, BETRIU C, GOMEZ M, RODRIGUEZ-AVIAL I, SANCHEZ BA; Interscience Conference on Antimicrobial Agents and Chemotherapy (43rd: 2003: Chicago, Ill.).

Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2003 Sep 14-17; 43: abstract no. E-1526.

Hospital Clinico San Carlos, Madrid, Spain.

BACKGROUND: The increasing incidence of methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a significant clinical concern. New antimicrobials are needed as alternatives in the treatment of infections caused by these organisms. Tigecycline is a semi-synthetic analogue of minocycline with a wide spectrum of activity against aerobic and anaerobic bacteria. METHODS: The activity of tigecycline was evaluated by the NCCLS reference agar dilution method against 215 nonduplicate MRSA isolates collected in our hospital. This activity was compared with that of minocycline, tetracycline, erythromycin, clindamycin, quinupristin/dalfopristin, rifampin, levofloxacin, trovafloxacin, gentamicin, and vancomycin. RESULTS: The majority of strains were resistant to both erythromycin and clindamycin, and 60% were resistant to gentamicin. Quinupristin/dalfopristin had a range of 0.25-2 microg/ml and an MIC[50] and MIC[90] both of 0.5 microg/ml. More than 75% of strains were resistant to levofloxacin. Trovafloxacin was 3 to 4-fold more active than levofloxacin. The activity of tigecycline was comparable to that of vancomycin (MIC[90,] 1 microg/ml). The glycylcycline inhibited all MRSA strains tested between 0.12 and 2 microg/ml. All tetracycline-resistant isolates (MICs, 16-64 microg/ml) and minocycline-resistant strains (MICs, 8-16 microg/ml) were inhibited by the new agent at 0.5 microg/ml. CONCLUSIONS: Tigecycline proved very active against all strains tested including those resistant to tetracycline, minocycline, erythromycin, clindamycin, gentamicin, levofloxacin or rifampin. The excellent activity and the absence of cross-resistance with other antimicrobials suggest a potential role for tigecycline in the treatment of infections due to multidrug resistant isolates such as MRSA.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Anti-Infective Agents
  • Fluoroquinolones
  • In Vitro
  • Microbial Sensitivity Tests
  • Minocycline
  • Ofloxacin
  • Staphylococcal Infections
  • Staphylococcus aureus
  • Virginiamycin
  • dalfopristin
  • quinupristin
  • tigecycline
  • trovafloxacin
Other ID:
  • GWAIDS0026306
UI: 102265930

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov